Earlier this year, Cullinan said its lead candidate hit the bull's-eye in a midstage lung cancer cancer trial but stayed mum on the details. Now, the biotech is revealing the results that have ...

With Illumina currently banned from shipping its DNA sequencers into China—in retaliation for the Trump administration’s ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

Only three months after banking an eye-popping $350 million series D round, Eikon Therapeutics is blaming government funding ...

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

French biotech OSE Immunotherapeutics is taking charge of a new project aimed at fast-tracking nanodrug development and ...

When mice implanted with metastasis-prone human cancer cells were treated with compounds that targeted ACBP’s activity, none ...

Having already worked with clinical trial sites in more than 14 states, CTAC will now take its work nationwide, the ...

We hoped industry layoffs would relent in 2024. That's not what happened. Overall, biopharma layoffs rose 3% last year compared to 2023, according to an analysis of yearly data. So, here we are ...

A Hong Kong-based developer of a catalog of urine-based tests for cancer, infectious diseases, women’s health and more has ...

Medtronic plans to separate from its diabetes business and launch it as an independent company—one that will count more than ...

Despite Merck KGaA’s lupus drug failing to prove itself against one form of the autoimmune disease, the German drugmaker has ...